Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. Studies establishing the efficacy of Ambrisentan included patients with both idiopathic or heritable pulmonary arterial hypertension and those with pulmonary arterial hypertension associated with connective tissue diseases. Patients studied displayed symptoms and etiologies predominantly of WHO Functional Class II-III. As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.

Market Analysis and Insights: Global and Japan Ambrisentantable Market
This report focuses on global and Japan Ambrisentantable market.
In 2020, the global Ambrisentantable market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. In Japan the Ambrisentantable market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Ambrisentantable Scope and Market Size
Ambrisentantable market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Ambrisentantable market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For Japan market, this report focuses on the Ambrisentantable market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in Japan.

Segment by Type
5 mg Tablet
10 mg Tablet

Segment by Application
Cirrhosis Of The Liver
High Blood Pressure
Hepatorenal Syndrome
Graft Function Is Delayed
Pulmonary Hypertension
Heart Failure
Chronic Renal Failure
Idiopathic Pulmonary Fibrosis
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
GSK
Actavis (TEVA )
Gilead Sciences
Mylan Pharmaceuticals
Sigmapharm Laboratories
Noorik BioPharma
Cipla
Cadila Healthcare
Sun Pharmaceutical Industries
Hansoh Pharma
CTTQ
Zhejiang Haosen Pharmaceutical